Visual dysfunctions have previously been reported in Parkinson’s disease and Huntington’s chorea. To further characterize the pathophysiology of vision in basal ganglion diseases, we studied visual functions in focal dystonic syndromes. Colour discrimination and visual contrast perception were investigated in 37 patients with focal idiopathic dystonia (ID; 20 spasmodic torticollis, 17 blepharospasm) and in age- and sex-matched healthy volunteers using the Farnsworth-Munsell 100-hue test and stationary contrast targets (Vistech plates). The mean total error score as well as the partial scores for the ‘red-green’ and the ‘blue-yellow’ axes in the Farnsworth-Munsell 100-hue test of the patients with ID were significantly elevated as compared to controls (spasmodic torticollis mean total error score 90.9 ± 67.6, controls: 16.6 ± 10.2; blepharospasm mean total error score 119.4 ± 78.6, controls: 22.7 ± 7.9). Additionally, the spatial contrast sensitivity was impaired in patients as compared to controls. The results indicate that the visual system is affected in ID. The visual disorder may be related to an imbalance of certain neurotransmitters in the visual system of patients, e.g. in the catecholaminergic pathways.

Keywords:
Chromatic vision, Colour discrimination, Farnsworth-Munsell 100-hue test, Contrast sensitivity
1.
Bodis-Wollner I, Yahr M: Measurement of visual evoked potentials in Parkinson’s disease. Brain 1978;101:661–671.
2.
Bodis-Wollner I, Marx MC, Mitra S, Bobak P, Mylin L, Yahr M: Visual dysfunction in Parkinson’s disease: Loss in spatiotemporal contrast sensitivity. Brain 1982;110:1675–1698.
3.
Büttner Th, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru D, Przuntek H: Disturbance of colour perception in Parkinson’s disease. J Neural Transm (PD Sect) 1993;6:11–15.
4.
Price MJ, Feldman RG, Adelberg D, Kayne H: Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology 1992;42:887–890.
5.
Galardi G, Perami D, Grassi F, Bressi S, Amadio S, Antoni M, Comi GC, Canal N, Fazio F: Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. Acta Neurol Scand 1996;94:172–176.
6.
Scheidt CE, Schuller B, Rayki O, Kommerell G, Deuschl G: Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm. Neurology 1996;47:43–45.
7.
Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB: Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;ii:245–246.
8.
Elston JS: Botulinum toxin A in clinical medicine. J Physiol (Paris) 1990;84:285–289.
9.
Farnsworth D: The Farnsworth-Munsell 100-hue and dichotomous test for color vision. J Opt Soc Am 1943;33:568–578.
10.
Verriest G, van Laethem J, Uvijls A: A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores. Am J Ophthalmol 1982;93:635–642.
11.
Smith VC, Pokorny J, Pass AS: Color-axis determination on the Farnsworth-Munsell 100-hue test. Am J Ophthalmol 1985;100:176–182.
12.
Ginsburg AP: A new contrast sensitivity vision test chart. Am J Opt Physiol Opt 1984;61:403–407.
13.
Drance SM, Lakowski R, Schulzer M, Douglas GR: Acquired color vision changes in glaucoma. Use of 100-hue test and Pickford anomaloscope as predictors of glaucomatous field change. Arch Ophthalmol 1981;99:829–831.
14.
Kinnear PR, Aspinal PA, Lakowski R: The diabetic eye and colour vision. Trans Ophthalmol Soc UK 1972;92:69–78.
15.
Livingstone MS, Hubel DH: Psychophysical evidence for separate channels for the perception of form, color, movement and depth. J Neurosci 1987;7:3416–3468.
16.
Lueck CJ, Zeki S, Friston KJ, Deiber MP, Cope P, Cunningham VJ, Lammertsma AA, Kennard C, Frackowiak RSJ: The colour centre in the cerebral cortex of man. Nature 1989;340:386–388.
17.
Meadows JC: Disturbed perception of colours associated with localized cerebral lesions. Brain 1974;98:615–632.
18.
Zeki S: A century of cerebral achromatopsia. Brain 1990;113:1721–1777.
19.
Büttner Th, Kuhn W, Patzold T, Przuntek H: L-Dopa improves colour vision in Parkinson’s disease. J Neural Transm (PD Sect) 1994;7:13–19.
20.
Harnois C, Di Paolo T: Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophtalmol Vis Sci 1990;31:2473–2475.
21.
Struck LK, Rodnitzky RL, Dobson JK: Circadian fluctuations of contrast sensitivity in Parkinson’s disease. Neurology 1990;40:467–470.
22.
Büttner Th, Kuhn W, Müller Th, Heinze T, Pühl C, Przuntek H: Chromatic and achromatic visual evoked potentials in Parkinson’s disease. Electroencephalogr Clin Neurophysiol 1996;100:443–447.
23.
Dowling JE: Functional and pharmacological organization of the retina: Dopamine interplexiform cells and neuromodulation; in Cohen B, Bodis-Wollner I (eds): Vision and the Brain. New York, Raven Press, 1990, pp 1–18.
24.
Büttner Th, Schulz S, Kuhn W, Blumenschein A, Przuntek H: Impaired colour discrimination in Huntington’s disease. Eur J Neurol 1994;1:153–157.
25.
Hinse P, Leplow B, Humbert T, Lamparter U, Junge A, Emskötter T: Impairment of visuospatial function in idiopathic spasmodic torticollis. J Neurol 1996;243:29–33.
26.
Hornykiewicz O, Kish SJ, Becker LE: Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med 1986;315:347–353.
27.
Jankovic J, Svendsen CN, Bird CE: Brain neurotransmitters in dystonia. N Engl J Med 1987;316:278–279.
28.
Fross RD, Martin WRW, Li D, Stoessl AJ: Lesions of the putamen: Their relevance to dystonia. Neurology 1987;37:80–84.
29.
Stoessl AJ, Martin WRW, Clark C, Adam MJ, Ammann W, Beckmann JH, Bergstrom M, Harrop R, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB: PET studies of cerebral glucose metabolism in idiopathic torticollis. Neurology 1986;36:653–657.
30.
Crossmann AR, Sambrock MA: Experimental torticollis in the monkey produced by 6-hydroxydopamine brain lesions. Brain Res 1978;149:498–502.
31.
Brücke T, Wenger S, Asenbaum S: Dopamine D2 receptor imaging and measurements with SPECT. Adv Neurol 1993;60:494–499.
32.
Crooks J, Kolb H: Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina. J Comp Neurol 1992;315:287–302.
33.
Benecke R, Strunper P, Weiss H: Electron transfer complex I defect in idiopathic dystonia. Ann Neurol 1992;9:642–649.
34.
Novotny EJ Jr, Singh G, Wallace DC, Dorfman LJ, Louis A, Sogg RL, Steinman L: Leber’s disease and dystonia: A mitochondrial disease. Neurology 1986;29:364–369.
35.
Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990;54:823–827.
36.
Brennan WA, Bird ED, Aprille JR: Regional mitochondrial respiratory activity in Huntington’s disease brain. J Neurochem 1995;44:1948–1950.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.